Prosecution Insights
Last updated: November 04, 2026
Application No. 18/253,803

ENCODED ASSAYS

Final Rejection §103§112
Filed
May 22, 2023
Priority
Nov 23, 2020 — provisional 63/116,997 +6 more
Examiner
DAUNER, JOSEPH G
Art Unit
1682
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Pleno Inc.
OA Round
2 (Final)
57%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
92%
With Interview

Examiner Intelligence

Grants 57% of resolved cases
57%
Career Allowance Rate
422 granted / 742 resolved
-3.1% vs TC avg
Strong +36% interview lift
Without
With
+35.5%
Interview Lift
resolved cases with interview
Typical timeline
3y 2m
Avg Prosecution
54 currently pending
Career history
824
Total Applications
across all art units

Statute-Specific Performance

§101
12.6%
-27.4% vs TC avg
§103
28.4%
-11.6% vs TC avg
§102
15.8%
-24.2% vs TC avg
§112
32.4%
-7.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 742 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . The amended claims filed 6/26/2026 are under consideration. The claims are not properly annotated. The phrase “and a unique molecular identifier (UMI) sequence” in part (b) of claim 1 is both underlined and struck through. In an interview with Tian Yong Zheng on 8/17/2026, it was confirmed that the text in question is not intended to be part of the claim. The amendments and arguments presented in the papers filed 6/26/2026 ("Remarks”) have been thoroughly considered. The issues raised in the Office action dated listed below have been reconsidered as indicated. a) The objection to the abstract is withdrawn in view of the amendments to the abstract. b) The rejection of claim(s) 1, 3, 5, 9, 10, 12, 13, 14, 23, 41, 157, 158, 159 and 160 under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by Zhang (WO 2017/177017) are withdrawn in view of the amendments incorporating elements of now cancelled claim 156. c) The rejections of claim(s) 38, 39, 40, 156 and 161 under 35 U.S.C. 103 as being unpatentable over Zhang (WO 2017/177017) in view of Shapero (WO 2018/223053 A1), because neither reference describes a bisulfite converted methylated nucleic acid sequence. The Examiner’s responses to the Remarks regarding issues not listed above are detailed below in this Office action. New and modified grounds of rejection necessitated by amendment are detailed below and this action is made FINAL. Priority The present application is a 371 national stage entry of PCT/US2021/060647 (filed 11/23/2021). The application also claims benefit to US provisional applications: 63/116,997; 63/126,414; 63/157,924; 63/183,876, 63/222,963; and 63/234,635; The Remarks argue the ‘997 provisional application supports claims 38, 39, 156 and 157, but is silent regarding support for independent claim 1. The Remarks argue the ‘414 provisional application supports claims 157, 158 and 159, but is silent regarding support for independent claim 1. The Remarks argue the ‘924 provisional application provides support by disclosing a padlock probe. The padlock probe disclosed supports the “recognition element” of claim 1. The ‘924 provisional application does not support bisulfite converted methylated nucleic acid sequences. Thus, the ‘924 provisional application does not fully support independent claim 1. The Remarks argue the ‘876 provisional application supports claims 38, 39, 156, 157, 158 and 159, but is silent regarding support for independent claim 1. The Remarks argue the ‘963 provisional application supports steps (b)-(d) of claim 1. The ‘963 provisional application does not support bisulfite converted methylated nucleic acid sequence. Thus, the ‘963 provisional application does not fully support independent claim 1. The Remarks argue the ‘635 provisional application supports steps (b)-(d) of claim 1. The ‘635 provisional application also describes bisulfite conversion followed by padlock probe ligation. While as a combination, the provisional applications provide support for independent claim 1, the effective filing date is based on the earliest disclosure of the combination of the elements claim 1. The earliest disclosure of step (a) is in the ‘635 provisional application. Thus, independent claim 1 and its dependent claims are given the earliest effective filing date of 8/18/2021, which is the filing date of the ‘635 provisional application. Information Disclosure Statement The listing of references in the specification or the citation of references throughout the specification is not a proper information disclosure statement. 37 CFR 1.98(b) requires a list of all patents, publications, or other information submitted for consideration by the Office, and MPEP § 609.04(a) states, "the list may not be incorporated into the specification but must be submitted in a separate paper." Therefore, unless the references have been cited by the examiner on form PTO-892 or cited on a submitted IDS, they have not been considered. Claim Rejections - 35 USC § 112 The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 2 and 38-41 rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The following rejection has been modified as necessitated by the amendments to the claim. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Claim 2 requires an “exonuclease cleanup step” after step (c). The claim broadly encompasses carrying out the “exonuclease cleanup step” after the “rolling circle amplification” element of step (d) or after the “subjecting” of step (e). The instant specification does not describe how to perform an exonuclease cleanup step in the presence of a rolling circle amplification product, which would be single stranded. The instant specification does not describe how to protect a rolling circle amplification product from exonuclease activity. One would have not reasonably found applicant to be in possession of a method in which a rolling circle amplification product is subjected to exonuclease treatment. The instant specification fails to provide support for claim 2 in view of the 1/2/2024 supplemental amendments to the claims. The instant specification describes subjecting PCR reactions to exonuclease treatment to remove unused primers, unreacted probes and other single-stranded nucleic acids, but not double-stranded PCR products. The instant specification describes treating circularized probes to exonuclease treatment to remove single-stranded targets, but this is prior to amplification of the circularized probe sequences. Thus, claim 2 encompasses new matter. The following are new rejections necessitated by the amendments. Claims 38-41 encompass methods in which step (b) encompasses hybridizing a recognition element to: 1) a bisulfite converted methylated nucleic acid sequence in the sample; and 2) a mutated sequence, a point mutation, a substitution, insertion and/or deletion and/or a copy number variation in the sample. The instant specification contemplates separate embodiments in which methylation is analyzed via providing a sample with bisulfite converted methylated nucleic acid sequence or mutations are analyzed using nucleic acids that have not been treated with bisulfite. The specification further describes an embodiment in which the sample is split into two separate streams, one for methylation analysis and one for non-methylation analysis. See Fig. 6, para. 379. Embodiments in which both methylation and mutations are analyzed in a sample comprising bisulfite converted nucleic are new matter. Response to the traversal of the written description rejection The Remarks argue claim 2 has been amended and is supported by Fig. 9, 15 and 22 and paragraph 372 (p. 9). The arguments have been fully considered but are not persuasive. The claim as amended broadly encompasses carrying out the “exonuclease cleanup step” after the rolling circle amplification step and thus, still encompasses the subject matter that was previously the basis for the written description rejection. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 12 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Regarding claim 12, the claim states a “3-ary nucleotide alphabet comprising three of A, C, G and T”. Based on the use of the term “comprising” the “3-ary nucleotide alphabet” may include additional elements. It is unclear if a fourth nucleotide is encompassed by “3-ary nucleotide alphabet”. Response to the traversal of the 112(b) rejection The Remarks argue the amendments to claim 12 overcome the rejection and the claim is based on the specification describing generating codes using a constrained alphabet of fewer than four nucleotides (p. 9). The arguments have been fully considered but are not persuasive. The claim is not drawn to a “3-ary nucleotide alphabet” using fewer than four nucleotides, as the “3-ary nucleotide alphabet” “comprises” three of A, C, G and T. The claim is interpreted as encompassing a “3-ary nucleotide alphabet” having at least 3 of A, C, G and T. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention. Claim(s) 1-3, 5, 9-10, 12-14, 23, 38-41 and 157-161 is/are rejected under 35 U.S.C. 103 as being unpatentable over Zhang (WO 2017/177017; previously cited) in view of Buis (WO 2018/094031 A1). The following are new rejections necessitated by the amendments. Regarding claims 1, 2, 38, 39, 40, and 161, Zhang teaches providing a sample with a target and hybridizing a capture pair to the target nucleic acid as a “recognition element”. Zhang further teaches the capture pair is then circularized or “transformed” into a “circular recognition element” using a variety of methods. Zhang teaches the circular molecule includes a primer binding site and using rolling circle amplification to produce a long concatemer extension product suitable for sequencing. See p. 40, lines 10-21. Zhang teaches the amplified circular molecule is detected using sequencing (p. 40, line 22-25). Zhang further teaches the “recognition element” includes a “code” from a set in the form of a Zip barcode (p. 41, lines 5-30). Regarding claim 3, Zhang teaches “counting” barcodes and “estimating” the quantity of the target by scoring the variant/SNP and Zip barcode (p. 41, lines 12-30). See also, p. 48, lines 1-8. Regarding claim 5, Zhang teaches the barcodes have a length of 3 to 30 nucleotides, inclusive (p. 21, lines 28-30). Regarding claim 9, Zhang teaches the barcodes are homopolymer free (p. 21, lines 18-27). Regarding claim 10, Zhang teaches barcode sequences, such as GTCAGTCAGTCA (p. 21, lines 18-27), which has all the structural elements of code formed from a 4-ary nucleotide alphabet of A, C, G and T. It is noted that claim 10 does not require an active method step of generating a set of codes. The language is interpreted as describing the structure of the codes based on how they are made. The claim broadly encompasses any code having the structure implied by the process, regardless of how the codes of the prior art are made. Regarding claim 12, Zhang teaches barcode sequences, such as GTCAGTCAGTCA (p. 21, lines 18-27), which has all the structural elements of code formed from a 3-ary nucleotide alphabet comprising three A, C, G and T. It is noted that claim 12 does not require an active method step of generating a set of codes. The language is interpreted as describing the structure of the codes based on how they are made. The claim broadly encompasses any code having the structure implied by the process, regardless of how the codes of the prior art are made. Regarding claim 13, Zhang teaches barcode sequences, such as GTCAGTCAGTCA (p. 21, lines 18-27), which has all the structural elements of code generated using a “4-state encoding trellis with 3 transitions per state”. It is noted that claim 13 does not require an active method step of generating a set of codes. The language is interpreted as describing the structure of the codes based on how they are made. The claim broadly encompasses any code having the structure implied by the process, regardless of how the codes of the prior art are made. Regarding claim 14, Zhang teaches the “recognition elements” includes a universal primer “associated” with the “code” (p. 22, lines 10-31; p. 23, lines 1-7). Regarding claim 23, Zhang teaches ligating the termini of the capture pair using the target as a guide to orientate the termini in the proper orientation (Fig. 1 and 2). Regarding claim 41, Zhang teaches the target may be part of an aneuploidy (p. 7, lines 1-5; p. 24, lines 7-11). Regarding claim 157, Zhang teaches the sequencing uses fluorescent nucleotides or oligonucleotides which involves measuring fluorescent in order to sequence the molecules (p. 4, lines 5-10; p. 37, lines 7-16). Regarding claim 158, Zhang teaches the “coded targets” include a universal priming sequence (p. 38, line 11-15) as a “sequencing adapter” and performing sequencing as noted above. Regarding claim 159, Zhang teaches immobilizing the “amplified codes” of the rolling circle amplification for sequencing (p. 46, lines 9-16; p. 53, lines 8-18) and measuring fluorescence as part of the sequencing process as noted above. Regarding claim 160, Zhang teaches the method is performed in a well of a substrate (p. 19, lines 20-25). While Zhang teaches the above method, Zhang does not teach a bisulfite converted methylated nucleic acid sequence as a target or the additional element specific to claims 2, 38, 40 and 161. However, Buis teaches molecular inversion probes are used to capture bisulfite converted methylated nucleic acid sequences (p. 13, 49 and 66-67). Buis further teaches thousands of targets are analyzed (p. 32-33, 53 and 73). Buis further teaches thousands of different short nucleotide sequence tags are used to identify a nucleic acid (p. 34). Buis further teaches targets in samples include point mutations, insertions and deletions, copy number variants, chromosomal translocations and inversions (p. 1 and 7). Buis further teaches using an exonuclease to digest non-circular, linear nucleic acids done after ligation and before amplification (p. 74, 78 and 88). It would have been obvious to the ordinary artisan at the time of filing to have modified the method of Zhang by detecting different types of variants using the probes of Zhang and/or detecting hundreds of targets described by Buis. The modifications have a reasonable expectation of success as each one is an obvious variant of the teaching of Buis that demonstrate the each are functionally equivalent as they detect a variant of interest. Conclusion No claims allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to JOSEPH G DAUNER whose telephone number is (571)270-3574. The examiner can normally be reached 7 am EST to 4:30 EST with second Fridays Off. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Wu-Cheng Winston Shen can be reached at 5712723157. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JOSEPH G. DAUNER/ Primary Examiner, Art Unit 1682
Read full office action

Prosecution Timeline

May 22, 2023
Application Filed
Jan 27, 2026
Non-Final Rejection mailed — §103, §112
Jun 26, 2026
Response Filed
Aug 17, 2026
Examiner Interview (Telephonic)
Aug 28, 2026
Final Rejection mailed — §103, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12766158
Methods of Treatments Based Upon Anthracycline Responsiveness
5y 0m to grant Granted Oct 20, 2026
Patent 12767990
EPLIN AS A BIOMARKER FOR CANCER
4y 0m to grant Granted Oct 20, 2026
Patent 12767976
NUCLEIC ACID CONTROL MOLECULES FROM NON-HUMAN ORGANISMS
2y 7m to grant Granted Oct 20, 2026
Patent 12760372
METHODS AND KITS FOR DETERMINING THE RISK OF BREAST CANCER RECURRENCE
4y 0m to grant Granted Oct 13, 2026
Patent 12760359
METHODS AND SYSTEMS FOR DETERMINING SEQUENCING READ DISTANCES
3y 5m to grant Granted Oct 13, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
57%
Grant Probability
92%
With Interview (+35.5%)
3y 2m (~0m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 742 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month